NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines.

With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

Company Growth (employees)
Edinburgh, GB
Size (employees)
19 (est)
NuCana was founded in 2008 and is headquartered in Edinburgh, GB

Key People at NuCana

Hugh S. Griffith

Hugh S. Griffith

Co-Founder, CEO & Board Member
Ian Abercrombie

Ian Abercrombie

Business Unit Director
Chris Wood

Chris Wood

Executive Chairman & Medical Director

NuCana Office Locations

NuCana has an office in Edinburgh
Edinburgh, GB (HQ)
10 Lochside Place

NuCana Data and Metrics

Summary Metrics

Founding Date


Total Funding

$67.5 m

Latest funding size

$57 m

Time since last funding

over 3 years


NuCana's latest funding round in April 2014 was reported to be $57 m. In total, NuCana has raised $67.5 m

NuCana Financial Metrics


Net income (FY, 2015)

(5.3 m)

Cash (31-Dec-2015)

29.2 m
GBPFY, 2015

Pre tax profit

(6.5 m)

Net Income

(5.3 m)
GBPFY, 2014FY, 2015


36.4 m29.2 m

Accounts Receivable

639.5 k148.8 k

Current Assets

37.1 m30.7 m


11.6 k14.5 k


462.2 k926.9 k

Total Assets

37.5 m31.7 m

Accounts Payable

726.7 k507.6 k

Current Liabilities

726.7 k1.7 m

Total Liabilities

726.7 k1.7 m

Retained Earnings

(5.3 m)

Total Equity

36.8 m30 m

Financial Leverage

1 x1.1 x
GBPFY, 2015

Cash From Operating Activities

(4.5 m)

Income Taxes Paid

1.2 m
Y, 2015

Financial Leverage

1.1 x

Traffic Overview of NuCana

NuCana Online and Social Media Presence

NuCana Company Life and Culture

You may also be interested in